Treatment with antibodies against T-lymphocytes usually triggers a febrile response potentially mimicking or masking infection. Procalcitonin (PCT) is considered a sensitive and specific marker of systemic bacterial and fungal infection. It was the aim of this study to investigate the characteristics of PCT and C-reactive protein (CRP) during treatment with polyclonal or monoclonal anti-Tcell antibodies, in order to examine the ability of these parameters to distinguish between systemic bacterial infection and reaction to antibody treatment. Thus, 15 consecutive febrile episodes after T-cell antibody infusion without clinical signs of infection were compared with nine episodes of Gram-negative sepsis. After T-cell antibody infusion PCT and CRP serum levels increased to a similar extent as in Gram-negative sepsis. Therefore, during T-cell antibody treatment neither PCT nor CRP are adequate for differentiating between fever due to infection or to unspecific cytokine release. Bone Marrow Transplantation (2003) 32, 941-945.
nin; CRP; sepsis Treatment with polyclonal (ATG) or monoclonal (OKT 3) T-cell antibodies is an integral part of numerous conditioning regimens for allogeneic stem cell transplantation (SCT) and of conventional therapy for severe aplastic anaemia (SAA). Febrile responses after the first doses of T-cell antibodies pose a diagnostic dilemma in these patients who are frequently neutropenic. 1 CRP is known as a nonspecific marker unable to distinguish between bacterial or fungal infection and other causes of fever during neutropenia, including certain viral infections, fever related to the underlying malignancy or to engraftment. [2] [3] [4] Recent publications suggest an even higher diagnostic value of procalcitonin (PCT). [4] [5] [6] [7] [8] However, there are sporadic reports on high PCT levels in adult patients after T-cell antibody infusion following kidney transplantation with no evidence of infection. [9] [10] [11] To further investigate these observations, we analysed the characteristics of PCT and CRP serum levels in paediatric patients with haematological or oncological diseases during treatment with T-cell antibodies and compared these with those occurring with episodes of Gram-negative sepsis. Furthermore, the roles of cytotoxic chemotherapy, irradiation and blood products were examined in the context of other potential stimuli for the release of these parameters.
Patients and methods
In all, 24 episodes of either Gram-negative sepsis or T-cell antibody treatment in 21 paediatric patients with haematological or oncological disorders were included in this study. Patient characteristics and underlying diseases are shown in Table 1 .
Group A consisted of 15 consecutive febrile episodes in 15 patients treated with T-cell antibodies between October 1998 and July 2001. Four patients received Thymoglobuline Merieux s (0.75 ml/kg/day), for 2, 4 (two patients) or 8 days, six ATG-Fresenius s (5 mg/kg/day) for 4 days and five OKT 3 (daily dose escalation from 0.01 mg/kg to a final dose of 0.1 mg/kg/day on day 4) for 14-21 days either as part of the conditioning regimen prior to allogeneic SCT or as conventional treatment for SAA (n ¼ 1). T-cell antibodies were administered as a 4-6 h infusion. In addition, cyclophosphamide (n ¼ 12), busulphan (n ¼ 6), thiotepa (n ¼ 4), etoposide (n ¼ 3), fludarabine (n ¼ 1) and total body/lymphoid irradiation (n ¼ 4) were used as conditioning therapy for SCT starting before (n ¼ 12), simultaneously with (n ¼ 1) or after (n ¼ 1) the first antibody administration. Five patients received blood products (platelet transfusions/n ¼ 4, packed erythrocyte transfusions/n ¼ 3) on the first day of T-cell antibody treatment. In all cases, T-cell antibody infusion was accompanied by steroid administration. Seven patients received cyclosporin A as GvHD prophylaxis, starting on the first (n ¼ 2), fourth (n ¼ 4) or sixth (n ¼ 1) day of antibody treatment.
Collection of blood samples for determination of inflammatory markers was commenced at the beginning of conditioning therapy and was performed daily for at least 3 weeks. Baseline PCT levels measured prior to the first T-cell antibody infusion were available for 14/15 patients. Blood for the first determination of inflammatory markers after starting T-cell antibody treatment was drawn 13-22 (median 18) h after the start of antibody infusion. Prior to T-cell antibody treatment, the white blood count (WBC) was 400-34.600/ml (median 2200/ml).
No physical signs or symptoms of infection other than fever were observed. Microbiological findings were unremarkable.
Group B comprised nine consecutive episodes of Gramnegative sepsis in nine patients between January 1999 and February 2001. Sepsis was defined according to the ACCP/ SCCM Consensus Conference Committee guidelines 12 adapted for children 13 (infection þ two or more of the following: temperature 438 or o361C, heart rate or respiratory rate above 2 Â s.d.). In addition, microbiological proof of Gram-negative bacteraemia was required for inclusion. Blood cultures grew Escherichia coli (n ¼ 3), Klebsiella pneumoniae (n ¼ 2), Pseudomonas aeruginosa, Stenotrophomonas maltophilia, Enterobacter sakazakii and Proteus mirabilis (n ¼ 1, each). The WBC on the day of fever onset was 100-1500/ml (median 150/ml).
In all patients with Gram-negative sepsis blood for the first PCT and CRP determination was drawn simultaneously with blood samples for microbiological cultures prior to the start of empirical antibiotic therapy (meropenem n ¼ 8, imipenem/cilastatin n ¼ 2, additional netilmicin n ¼ 5). Follow-up blood samples were drawn every morning on the following 2-9 days, until clinical improvement.
In all patients, body temperature was measured at least five times daily.
Laboratory methods
CRP was measured turbidimetrically using the Hitachi 917 analytic device and reagents of Roche Diagnostics (Vienna, Austria), PCT was determined by means of an immunoluminometric assay (BRAHMS Diagnostika GmbH, Berlin, Germany).
Statistical analysis
Data are presented as medians and ranges or as counts and proportions. Considering other potential stimuli than T-cell antibodies for the release of PCT and CRP, we also examined the influence of cytotoxic chemotherapy and radiation treatment. The increase of PCT and CRP serum levels vs baseline was calculated for each component of conditioning therapy using the following formula: (level of the day after first administrationÀbaseline level before administration)/baseline level. Differences were assessed using the Mann-Whitney U-test.
For assessment of diagnostic values receiver-operating characteristics (ROC) curves were calculated, and AUC was compared with a reference value of 0.5, indicating no diagnostic value.
Since the diagnosis of SAA occurred in group A only, additional statistical analysis was performed disregarding the six SAA patients, in order to exclude a possible bias caused by an uneven distribution of patient characteristics.
All computations were performed by means of SPSS for Windows 10.0.
Results
A total of 269 PCT (group A: 228, group B: 41) and 396 CRP (group A: 296, group B: 100) measurements of 24 episodes in 21 patients were evaluated.
Despite additional steroid administration, all 15 patients treated with T-cell antibodies became febrile 2-12 (median 5) h after the start of infusion (peak temperatures 37.7-40.71C/median 38.91C). In 11 episodes (78.5%), the body temperature exceeded 37.91C. In 10 episodes, the peak temperature was reached during the first 24 h. Defervescence was observed within 1-4 (median 2) days.
Similar peak temperatures (37.6-40.61C/median 39.51C) were measured during sepsis.
In group A (T-cell antibody-treated patients), PCT levels (n ¼ 228) were evaluated from the start of conditioning therapy until day 11 after the start of T-cell antibody treatment.
All PCT baseline levels prior to T-cell antibody infusion were below 1.0 ng/ml (o0.1-0.78, median 0.18 ng/ml). In 12 episodes, the baseline PCT was in the normal range (o0.5 ng/ml).
After T-cell antibody infusion the median increase in serum PCT exceeded the baseline level 39 times. In all but two cases blood samples collected 13-22 h (median 18 h) after starting the infusion showed PCT concentrations above the upper normal value with a maximum of 38.9 and a median of 7.15 ng/ml. Thereafter, PCT levels decreased and returned to normal between 2 and 11 (median 5.5) days after the start of T-cell antibody treatment. One patient developed a first PCT increase (1.2 ng/ml) later than 24 h after T-cell antibody infusion with no more concomitant conditioning treatment. The PCT remained within the normal range with T-cell antibody treatment in only one patient. In group B (septic patients), PCT levels (n ¼ 41) were evaluated from onset of fever for 3-10 days depending on the clinical course. On the first day after fever onset PCT levels were above the upper normal value in all septic patients (Table 2 ) and reached a maximum on day 1 (n ¼ 6), 2 (n ¼ 2) or 3 (n ¼ 1). Thus, a wide overlap was observed in the levels of T-cell antibody-treated patients. Neither PCT peak levels nor PCT concentrations on the 3 days after onset of fever differed significantly between septic patients and patients treated with T-cell antibodies (Figure 1) .
The ROC curve for PCT levels on the day after fever onset ( Figure 2a) showed an area under the curve of 0.552 (P ¼ 0.77), suggesting that PCT has no diagnostic value in predicting Gram-negative sepsis in patients receiving T-cell antibodies.
In group A, CRP levels (n ¼ 296) were evaluated from the start of conditioning therapy until day 14 after the start of T-cell antibody treatment.
CRP levels were elevated after T-cell antibody infusion in all patients, with peak values of up to 215.8 mg/l (14.0-215.8, median 40 mg/l). The median increase was four times the baseline. Peak levels were reached within 1 day in 10 patients, and CRP returned to normal at the earliest on day 4, with a median of day 7 after T-cell antibody infusion. In five patients, the CRP remained elevated for more than 20 days, independent of the duration of T-cell antibody treatment.
In group B, CRP levels were evaluated until at least 5 days after onset of fever (n ¼ 100). CRP concentrations peaked on the second (n ¼ 6) or third (n ¼ 3) day of fever and showed highest levels between 74 and 394 mg/l (median 129 mg/l). CRP levels on the 3 days after fever onset as well as the peak levels showed significant differences when compared with group A, with P-values of 0.003 and 0.018. However, there was a wide overlap between both groups (Figure 3) .
The ROC curve for differentiating T-cell antibody reaction from Gram-negative sepsis by CRP serum levels on day 1 after fever onset (Figure 2b) shows an area under the curve of 0.861 (P ¼ 0.005).
Using an optimized cutoff point of 62 mg/l, the sensitivity of CRP in indicating Gram-negative sepsis in this sample is 100%, while specificity is 60%.
Exclusion of the six patients with SAA (a diagnosis present in group A only) from statistical analysis had no significant influence on the results shown above.
There was no significant difference between T-cell antibody preparations (Thymoglobuline Merieux s , ATGFresenius s , OKT 3) concerning their influence on PCT and CRP levels; however, validity of the statistical evaluation is questionable due to the low number of patients in each subgroup.
No significant change of PCT or CRP levels was observed with any component of conditioning treatment except for T-cell antibodies (Table 3) .
Similarly, administration of blood products did not influence the inflammatory markers.
Discussion
Although PCT has been recognized as a rather specific marker of sepsis, 5, 6 there are also recent reports of high PCT levels after T-cell antibody infusion in adult renal transplant patients. [9] [10] [11] This evidence is confirmed and broadened by our data derived from paediatric patients with haematological or oncological diseases.
T-cell antibody treatment was followed by an increase in PCT levels in all patients. In 14 of 15 episodes (including the patient with conventional T-cell antibody treatment for SAA), PCT concentrations exceeded the upper normal value. For all 15 patients, the median PCT elevation on day 1 after T-cell antibody infusion was nearly 40 times the baseline.
In all, 14 patients received conditioning treatment in addition to T-cell antibodies, but no component of conditioning therapy except T-cell antibodies was followed by a significant increase in PCT levels, neither did blood products have any influence on serum levels of the inflammatory parameters.
On day 1 of T-cell antibody-related fever, when laboratory parameters are most relevant for therapeutic decisions, PCT even showed a tendency towards higher serum levels than in patients with Gram-negative sepsis, and during the entire course of the studied episodes the two groups were statistically indistinguishable by means of PCT levels. According to the ROC curve, PCT is not predictive of sepsis while T-cell antibody treatment is in progress. Thus, according to this study and to data derived from adult kidney transplant patients, PCT does not offer any diagnostic benefit in patients treated with T-cell antibodies.
Interestingly, CRP, which is commonly considered less specific than PCT, seems to have a higher diagnostic value in distinguishing T-cell antibody-related fever from sepsis. Yet, although significant differences are observed on the first 4 days after onset of fever and although the comparison between ROC curves seems to favour CRP, specificity of this parameter is insufficient, since there is also a marked influence of T-cell antibody treatment on CRP concentration, which causes a median increase of four times the baseline and a wide overlap with the levels measured in septic patients.
In summary, febrile episodes during treatment with T-cell antibodies go along with markedly elevated levels of PCT and CRP. There is a tendency toward higher serum levels of CRP during sepsis. However, this does not permit sufficient diagnostic value in clinical practice for the individual case. Thus, during T-cell antibody treatment, none of these parameters seems to be helpful in distinguishing fever due to infection from that caused by nonspecific cytokine release.
